Novel Pharmacotherapeutic Interventions for Cannabis Use Disorder

Mason, Brittany L.; Mustafa, Alaa; Filbey, Francesca M.; Brown, E. Sherwood

doi:10.1007/s40429-016-0094-y

Cited by 7 publications

(3 citation statements)

References 45 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…There are currently no suitable pharmacological treatments specifically for cannabis dependence (Allsop et al, 2015; Mason et al, 2016). Several psychosocial treatment models are in use, including cognitive-behavioral therapy, motivational-enhancement therapy, contingency management, and family-based therapies, all of which yield modest success rates (Brezing and Levin, 2017; Sherman and McRae-Clark, 2016).…”

Section: Introductionmentioning

confidence: 99%

Novel behavioral assays of spontaneous and precipitated THC withdrawal in mice

Trexler

Nass

Gross

et al. 2018

Drug and Alcohol Dependence

View full text Add to dashboard Cite

show abstract

Section: Introductionmentioning

confidence: 99%

Novel behavioral assays of spontaneous and precipitated THC withdrawal in mice

Trexler

Nass

Gross

et al. 2018

Drug and Alcohol Dependence

View full text Add to dashboard Cite

show abstract

“…Targets of these medications include (a) reduction in withdrawal or cessation of use with agonist-like medication that target the CB1 receptor (substitution therapies), (b) specific withdrawal symptoms or relapse triggers such as mood, sleep, or craving, (c) reduction in the reinforcing effects of cannabis with antagonist or inverse agonist medications that "block" the CB1 receptor or opioid receptors that interact with the cannabinoid system, and (f) comorbid psychiatric conditions that may partially contribute to ongoing use of cannabis to relieve psychiatric symptoms. Multiple reviews of this pharmacotherapy literature illustrate that we have yet to identify medications that are effective for engendering cannabis abstinence or significant reductions in use [6,82,[98][99][100][101]. Some positive signals of potential efficacy have been observed for a few medications, but replication studies have either failed to confirm the results or have not been reported.…”

Section: How Difficult Is It To Quit or Reduce Cannabis Use?mentioning

confidence: 99%

An update on cannabis use disorder with comment on the impact of policy related to therapeutic and recreational cannabis use

Budney¹,

Sofis²,

Borodovsky

2019

Eur Arch Psychiatry Clin Neurosci

View full text Add to dashboard Cite

Confusion and controversy related to the potential for cannabis use to cause harm, or alternatively to provide benefit, continues globally. This issue has grown in intensity and importance with the increased recognition of the public health implications related to the escalation of the legalization of cannabis and cannabinoid products. This selective overview and commentary attempt to succinctly convey what is known about one potential consequence of cannabis use, the development of cannabis use disorder (CUD). Such knowledge may help guide a reasonable and objective public health perspective on the potential impact of cannabis use and CUD. Current scientific data and clinical observation strongly support the contention that cannabis use, like the use of other substances such as alcohol, opioids, stimulants, and tobacco, can develop into a use disorder (addiction) with important clinical consequences. Epidemiological data indicate that the majority of those who use cannabis do not have problems related to their use, but a substantial subset (10-30%) do report experiencing symptoms and consequences consistent with a CUD. Treatment seeking for CUD comprises a substantial proportion of all substance use treatment admissions, yet treatment response rates show much room for improvement. Changing cannabis policies related to its therapeutic and recreational use are likely to impact the development of CUD and its course; however, definitive data on such effects are not yet available. Clearly, the development of more effective prevention and treatment strategies is needed for those vulnerable to developing a CUD and for those with a CUD.

show abstract

“…Cognitive behavioral therapies have seen modest short-term success in reducing CUD, with only 19-29% of individuals maintaining abstinence at a 12-month follow up (Budney, Vandrey, Hughes, Moore, & Bahrenburg, 2007;Ramesh & Haney, 2015). Unlike other commonly abused drugs, like opioids or nicotine, there are currently no FDA approved pharmacological therapies to relieve cannabinoid withdrawal symptoms (Allsop, Lintzeris, Copeland, Dunlop, & McGregor, 2015;Mason, Mustafa, Filbey, Brown, & Mason, 2016).…”

Section: Cannabis Use Disordermentioning

confidence: 99%

Acute and Repeated Effects of Synthetic Cannabinoid Agonism and Cannabinoid Receptor 1 Positive Allosteric Modulation

Trexler¹

View full text Add to dashboard Cite

Recent years have seen a rise in the diversity and use of synthetic cannabinoids. Currently, there is little known about the effects of specific synthetic cannabinoid compounds. As such, little research has been done evaluating the acute and chronic effects of synthetic cannabinoid administration or the development of tolerance and withdrawal. The present study aimed, in part, to evaluate the acute and repeated effect of a third-generation synthetic cannabinoid, AB-FUBINACA. Mice were treated with AB-FUBINACA (0.1-3 mg/kg, i.p.) or vehicle and were tested repeatedly in the tetrad battery of assays, which included tests of catalepsy, antinociception, hypothermia, and locomotor activity. A second group of mice was injected with AB-FUBINACA (3 mg/kg, s.c.) twice daily for 6 days and were tested daily in tetrad. On the 6 th day, withdrawal was precipitated using the cannabinoid receptor antagonist rimonabant (3 mg/kg), and behavior was scored in the somatic signs of withdrawal tests. AB-FUBINACA exhibited classic acute cannabinoid effects in the tetrad but showed a lack of tolerance and cross-tolerance to THC (50 mg/kg, i.p.). Further, precipitated withdrawal from AB-FUBINACA was of a much smaller magnitude than what is typical of other phyto-and synthetic cannabinoids. Another aspect of cannabinoid research that has been largely overlooked is the use of assays that are able to detect spontaneous (i.e., abstinence-induced) withdrawal. Previous research has demonstrated that spontaneous withdrawal can be detected with certain assays, like the somatic signs of withdrawal and tail suspension tests. To determine whether an anhedonia test would detect signs of spontaneous withdrawal, mice were trained to consume a sweetened condensed milk mixture over 9 days. During the final 6 days of training, mice were injected twice daily with THC (10 or 50 mg/kg, s.c.) or vehicle. On the 9 th day, injections were stopped and mice were tested again at 12h and 36h abstinence. No changes were observed as a result of spontaneous withdrawal from THC.

show abstract

Novel Pharmacotherapeutic Interventions for Cannabis Use Disorder

Cited by 7 publications

References 45 publications

Novel behavioral assays of spontaneous and precipitated THC withdrawal in mice

Novel behavioral assays of spontaneous and precipitated THC withdrawal in mice

An update on cannabis use disorder with comment on the impact of policy related to therapeutic and recreational cannabis use

Acute and Repeated Effects of Synthetic Cannabinoid Agonism and Cannabinoid Receptor 1 Positive Allosteric Modulation

Contact Info

Product

Resources

About